{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:14:23Z","timestamp":1761506063952,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5 KL2 RR025743"],"award-info":[{"award-number":["5 KL2 RR025743"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006521","name":"Stanford University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.cllc.2018.12.005","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T21:50:39Z","timestamp":1545342639000},"page":"e356-e361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Increased Galectin-1 Expression in Thymic Epithelial Tumors"],"prefix":"10.1016","volume":"20","author":[{"given":"Jonathan W.","family":"Riess","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina S.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert B.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhmani K.","family":"Padda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quynh-Thu","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2018.12.005_bib1","first-page":"161","article-title":"Primary mediastinal malignancies: findings in 219 patients","volume":"170","author":"Temes","year":"1999","journal-title":"West J Med"},{"key":"10.1016\/j.cllc.2018.12.005_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/CCO.0b013e32834ea6bb","article-title":"Multidisciplinary treatment of malignant thymoma","volume":"24","author":"Spaggiari","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.cllc.2018.12.005_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1385\/IR:21:2-3:71","article-title":"Regulation of T cell development in the thymus","volume":"21","author":"Kaye","year":"2000","journal-title":"Immunol Res"},{"key":"10.1016\/j.cllc.2018.12.005_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2018.12.005_bib5","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/JCO.2017.35.15_suppl.8521","article-title":"A\u00a0phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor","volume":"35","author":"Cho","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.12.005_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.clim.2011.09.011","article-title":"Galectin-1 research in T cell immunity: past, present and future","volume":"142","author":"Cedeno-Laurent","year":"2012","journal-title":"Clin Immunol"},{"key":"10.1016\/j.cllc.2018.12.005_bib7","doi-asserted-by":"crossref","first-page":"15975","DOI":"10.1073\/pnas.0603883103","article-title":"Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy","volume":"103","author":"Thijssen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cllc.2018.12.005_bib8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10555-012-9388-2","article-title":"Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment","volume":"31","author":"Ito","year":"2012","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.cllc.2018.12.005_bib9","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1158\/0008-5472.CAN-10-4157","article-title":"Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis","volume":"71","author":"Banh","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2018.12.005_bib10","article-title":"Targeting galectin-1 to improve therapeutic efficacy in head and neck cancers","volume":"5","author":"Nambiar","year":"2017","journal-title":"Tumor Immunol Immunother"},{"key":"10.1016\/j.cllc.2018.12.005_bib11","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.3748\/wjg.v19.i13.2073","article-title":"Clinicopathological and prognostic significance of galectin-1 and vascular endothelial growth factor expression in gastric cancer","volume":"19","author":"Chen","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cllc.2018.12.005_bib12","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1182\/blood-2012-12-474569","article-title":"Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma","volume":"121","author":"Ouyang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cllc.2018.12.005_bib13","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.ejca.2012.02.005","article-title":"High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2018.12.005_bib14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.humpath.2012.04.010","article-title":"Galectin 1 expression is associated with tumor invasion and metastasis in stage IB to IIA cervical cancer","volume":"44","author":"Kim","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cllc.2018.12.005_bib15","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1158\/1078-0432.CCR-11-3348","article-title":"Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2","volume":"18","author":"Chung","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2018.12.005_bib16","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1158\/0008-5472.CAN-12-2418","article-title":"Targeting galectin-1 overcomes breast cancer\u2013associated immunosuppression and prevents metastatic disease","volume":"73","author":"Dalotto-Moreno","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2018.12.005_bib17","first-page":"815","article-title":"Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications","volume":"147","author":"Xu","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cllc.2018.12.005_bib18","doi-asserted-by":"crossref","first-page":"13134","DOI":"10.1073\/pnas.0706017104","article-title":"The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma","volume":"104","author":"Juszczynski","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cllc.2018.12.005_bib19","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1084\/jem.185.10.1851","article-title":"Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes","volume":"185","author":"Perillo","year":"1997","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.cllc.2018.12.005_bib20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.hoc.2008.03.004","article-title":"Thymoma, myasthenia gravis, and other paraneoplastic syndromes","volume":"22","author":"Tormoehlen","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.cllc.2018.12.005_bib21","first-page":"669","article-title":"GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray","volume":"35","author":"Riess","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cllc.2018.12.005_bib22","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"issue":"10 suppl 4","key":"10.1016\/j.cllc.2018.12.005_bib23","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1097\/JTO.0b013e3181f20c05","article-title":"Staging system of thymoma","volume":"5","author":"Masaoka","year":"2010","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730418303292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730418303292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:09:21Z","timestamp":1761505761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730418303292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1525730418303292"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2018.12.005","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased Galectin-1 Expression in Thymic Epithelial Tumors","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2018.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}